Jyoti CNC Automation Regulatory Approval

Jyoti CNC Automation Earnings Call Transcript: Key Takeaways

Revenue rose 18.5% to ₹602 Cr, but consolidated EBITDA margin of 21.8% lags the standalone 28% because Huron revenue is held back. Management is assertive on the 25% margin and 8,000-machine target, with thin detail on Huron timing.

Jyoti CNC Automation Investor Presentation: Key Takeaways

Q2/H1 FY27 standalone: revenue INR 588 Cr (+31%), EBITDA margin 27.9%, PAT INR 115 Cr (+46%); record 1,900 machine dispatches, order book INR 5,082 Cr. Consolidated PAT fell 15%.

Jyoti CNC Automation Q2 FY27 Results: Net Profit ₹72.6 Cr, Down 15.1% YoY

Jyoti CNC Automation Ltd reported revenue from operations of ₹602 Cr (+18.5% YoY) and net profit of ₹72.6 Cr (-15.1% YoY) for Q2 FY27.

Key figure

Net profit ₹72.6 Cr · -15.1% YoY

Jyoti CNC Automation Board Meeting Date

Jyoti CNC Automation Ltd will hold a board meeting on November 03, 2026, to approve standalone and consolidated financial results for the quarter ended September 30, 2026.

Jyoti CNC Automation Credit Rating

Jyoti CNC Automation received credit ratings from CRISIL for its bank loan facilities, including A+/Stable for long-term and A1 for short-term debt.

Value

₹1,415 Cr

Jyoti CNC Automation Other Announcement

Jyoti CNC Automation Ltd has filed its quarterly shareholding pattern as mandated by SEBI. The report discloses the stake distribution among promoters and public shareholders.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.

John Cockerill India Regulatory Approval

John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.